Literature DB >> 18340403

Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I.

Kanako Sugawara1, Seiji Saito2, Kazuki Ohno3,4, Torayuki Okuyama5, Hitoshi Sakuraba6.   

Abstract

To elucidate the basis of mucopolysaccharidosis type I (MPS I), we constructed structural models of mutant alpha-L: -iduronidases (IDUAs) resulting from 33 amino acid substitutions that lead to MPS I (17 severe, eight intermediate, and eight attenuated). Then, we examined the structural changes in the enzyme protein by calculating the number of atoms affected and determined the root-mean-square distance (RMSD) and the solvent-accessible surface area (ASA). In the severe MPS I group, the number of atoms influenced by a mutation and the average RMSD value were larger than those in the attenuated group, and the residues associated with the mutations identified in the severe group tended to be less solvent accessible than those in the attenuated group. The clinically intermediate phenotype group exhibited intermediate values for the numbers of atoms affected, RMSD, and ASA between those in the severe group and those in the attenuated group. The results indicated that large structural changes had occurred in the core region in the severe MPS I group and small ones on the molecular surface in the attenuated MPS I group. Color imaging revealed the distributions and degrees of the structural changes caused by representative mutations for MPS I. Thus, structural analysis is useful for elucidating the basis of MPS I. As there was a difference in IDUA structural change between the severe MPS I group and the attenuated one, except for a couple of mutations, structural analysis can help predict the clinical outcome of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18340403     DOI: 10.1007/s10038-008-0272-4

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  27 in total

1.  Identification and characterization of -3c-g acceptor splice site mutation in human alpha-L-iduronidase associated with mucopolysaccharidosis type IH/S.

Authors:  Y N Teng; T R Wang; W L Hwu; S P Lin; G J Lee-Chen
Journal:  Clin Genet       Date:  2000-02       Impact factor: 4.438

2.  Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3.

Authors:  H S Scott; L J Ashton; H J Eyre; E Baker; D A Brooks; D F Callen; G R Sutherland; C P Morris; J J Hopwood
Journal:  Am J Hum Genet       Date:  1990-11       Impact factor: 11.025

3.  Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations.

Authors:  C E Beesley; C A Meaney; G Greenland; V Adams; A Vellodi; E P Young; B G Winchester
Journal:  Hum Genet       Date:  2001-10-19       Impact factor: 4.132

4.  A homology model for human alpha-l-iduronidase: insights into human disease.

Authors:  Brian P Rempel; Lorne A Clarke; Stephen G Withers
Journal:  Mol Genet Metab       Date:  2005-02-10       Impact factor: 4.797

5.  Mucopolysaccharidosis type I: identification of common mutations that cause Hurler and Scheie syndromes in Japanese populations.

Authors:  A Yamagishi; S Tomatsu; S Fukuda; A Uchiyama; N Shimozawa; Y Suzuki; N Kondo; K Sukegawa; T Orii
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

6.  Molecular analysis of 30 mucopolysaccharidosis type I patients: evaluation of the mutational spectrum in Italian population and identification of 13 novel mutations.

Authors:  N Venturi; A Rovelli; R Parini; F Menni; F Brambillasca; F Bertagnolio; G Uziel; R Gatti; M Filocamo; M A Donati; A Biondi; S Goldwurm
Journal:  Hum Mutat       Date:  2002-09       Impact factor: 4.878

7.  Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS IS and MPS IH/S).

Authors:  P T Tieu; G Bach; A Matynia; M Hwang; E F Neufeld
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

8.  alpha-L-iduronidase in normal and mucopolysaccharidosis-type-I human skin fibroblasts.

Authors:  J A Taylor; G J Gibson; D A Brooks; J J Hopwood
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

Review 9.  Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.

Authors:  H S Scott; S Bunge; A Gal; L A Clarke; C P Morris; J J Hopwood
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

10.  Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.

Authors:  G Yogalingam; X-H Guo; V J Muller; D A Brooks; P R Clements; E D Kakkis; J J Hopwood
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

View more
  3 in total

1.  Structural characterization of mutant alpha-galactosidases causing Fabry disease.

Authors:  Kanako Sugawara; Kazuki Ohno; Seiji Saito; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-07-17       Impact factor: 3.172

2.  Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I.

Authors:  Arunabha Ghosh; Aiyin Liao; Claire O'Leary; Jean Mercer; Karen Tylee; Anu Goenka; Rebecca Holley; Simon A Jones; Brian W Bigger
Journal:  Mol Ther Methods Clin Dev       Date:  2019-03-02       Impact factor: 6.698

3.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.